KR-20260064819-A - NOVEL STRAIN OF Lactiplantibacillus plantarum WB2324 STRAIN AND USE THEREOF

Abstract

The present invention relates to a novel Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P) having an anti-inflammatory effect in lung tissue and its use.

Inventors

• 백현동
• 이나경
• 김지훈
• 김기태

Assignees

• 건국대학교 산학협력단
• 주식회사 위드바이오

Dates

Publication Date

20260508

Application Date

20241029

Claims (10)

1. Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P) having anti-inflammatory effects in lung tissue.
2. In paragraph 1, The above WB2324 strain (KCCM 13507P) is i) Reduces the gene expression of Eotaxin chemokines in lung tissue; ii) WB2324 strain (KCCM 13507P) characterized by reducing the gene expression of one or more cytokines selected from the group consisting of TNF-α, IL-6, IL-1β, IL-4, IL-13, and IL-25 in lung tissue.
3. In paragraph 1, The above WB2324 strain (KCCM 13507P) is i) reduce one or more phosphorylation levels selected from the group consisting of p38, ERK 1/2, and JNK in lung tissue; ii) WB2324 strain (KCCM 13507P), characterized by reducing the phosphorylation level of p65 or IkB-α in lung tissue.
4. In paragraph 1, The above WB2324 strain (KCCM 13507P) is WB2324 strain (KCCM 13507P), characterized by reducing the production of reactive oxygen species (ROS) in lung tissue.
5. In paragraph 1, The above WB2324 strain (KCCM 13507P) is i) having acid resistance, bile resistance, and intestinal adhesion ability; ii) WB2324 strain (KCCM 13507P), characterized by having no hemolytic activity or bile salt hydrolyzing enzyme activity, and having susceptibility to antibiotics.
6. In paragraph 1, The above WB2324 strain (KCCM 13507P) is characterized by including a DNA base sequence encoding the 16S rRNA of SEQ ID NO. 1.
7. A pharmaceutical composition for the prevention or treatment of respiratory diseases comprising the Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P) or a culture solution thereof as an active ingredient.
8. In paragraph 1, A pharmaceutical composition characterized in that the above WB2324 strain is a dead cell.
9. In paragraph 8, A pharmaceutical composition characterized by the above-mentioned dead cell being prepared by culturing the above-mentioned WB2324 strain (KCCM 13507P) at 30°C to 40°C for 10 to 50 hours, and then heat-treating it at 60°C to 100°C for 5 minutes to 1 hour.
10. A health functional food composition for the prevention or improvement of respiratory diseases comprising the Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P) or a culture solution thereof as an active ingredient.

Description

Novel STRAIN OF Lactiplantibacillus plantarum WB2324 STRAIN AND USE THEREOF The present invention relates to a novel Lactibacillus plantarum WB2324 strain and its uses. Asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, cough suppressants, acute and chronic bronchitis, bronchiolitis, pharyngitis, tonsillitis, and laryngitis are representative respiratory diseases. Asthma refers to chronic inflammation occurring in the airways, specifically the bronchi. Inflammation caused by asthma can be exacerbated by a wide variety of predisposing factors, such as exhaust fumes, allergens, cold winds, exercise, and respiratory infections; persistent inflammation leads to airway deformation and hyperresponsiveness. Due to these causes, general symptoms appear, including wheezing (a whistling or rattling breathing sound caused by narrowed airways), shortness of breath, coughing, and the expulsion of excessive sputum. The respiratory tract is largely composed of mucosa and muscle called bronchial smooth muscle. The mucosa contains numerous glands that continuously secrete necessary substances, and when the bronchial smooth muscle contracts, the airway narrows. When an inflammatory response occurs due to a wide variety of predisposing factors, such as exhaust fumes, allergens, cold wind, exercise, and respiratory infections, secretions from the glands increase further. These secretions block the airway, causing the mucosa to swell inward and further narrow the airway. Consequently, severe paroxysmal coughing accompanied by wheezing and shortness of breath occur; during an attack, a dry cough develops and a sensation of chest tightness is felt. There are also many cases of asthma characterized solely by chronic coughing and chest tightness without wheezing, with symptoms of unknown cause; these symptoms tend to appear suddenly and paroxysmally during daily life. Various studies are being conducted using lactic acid bacteria, a type of probiotic, to prevent, treat, or improve such respiratory diseases. Figure 1 is a graph showing the mRNA expression of inflammation-related chemokines (Eotaxin) and inflammation-related cytokines (TNF-α, IL-6, IL-1β, IL-4, IL-13, IL-25) in A549 cell lines treated with L. plantarum WB2324. Figure 2 is a graph showing the production of inflammation-related chemokines (Eotaxin) and inflammation-related cytokines (TNF-α, IL-6) in A549 cell lines following treatment with L. plantarum WB2324. Figure 3 is a graph showing the regulation of the MAPK signaling pathway (phosphorylation of p38, ERK 1/2, and JNK) in A549 cell lines following treatment with L. plantarum WB2324. Figure 4 is a graph showing the regulation of the NF-kB signaling pathway (phosphorylation of p65, IkB-α) in A549 cell lines following treatment with L. plantarum WB2324. Figure 5 is a graph showing the reactive oxygen species (ROS) production capacity in A549 cell lines following treatment with L. plantarum WB2324. The inventors completed the present invention by isolating and identifying the Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P), which has a unique metabolic ability among Lactiplantibacillus plantarum strains having probiotic characteristics, and by specifically demonstrating in vitro that it has anti-inflammatory and antioxidant effects in lung tissue. The present invention will be described in detail below. Novel Lactibacillus plantarum WB2324 strain The present invention provides a Lactiplantibacillus plantarum WB2324 strain (KCCM 13507P) having an anti-inflammatory effect in lung tissue. The above WB2324 strain (KCCM 13507P) can be considered a type of Lactiplantibacillus plantarum strain. The above WB2324 strain (KCCM 13507P) was isolated from a traditional fermented food such as kimchi. As a result of analyzing 16S rRNA to identify the isolated strain, it was confirmed to have a DNA base sequence coding for the 16S rRNA of SEQ ID NO. 1. It was entrusted to the National Institute of Biotechnology and Bioengineering (NIBB) Biological Resource Center on August 28, 2024, and assigned accession number KCCM 13507P. The above WB2324 strain (KCCM 13507P) is effective against respiratory diseases, particularly inflammatory respiratory diseases, as it possesses unique metabolic capabilities among Lactiplantibacillus plantarum strains and exhibits anti-inflammatory and antioxidant effects in lung tissues. In other words, even if a strain belongs to the same genus as the above WB2324 strain (KCCM 13507P), it cannot be considered effective against respiratory diseases without proof through specific experiments. First, the above WB2324 strain (KCCM 13507P) is characterized by having a unique metabolic ability. Specifically, the above WB2324 strain (KCCM 13507P) may have i) acid resistance, bile resistance, and intestinal adhesion ability. More specifically, with respect to i), the acid resistance of the above WB2324 strain (KCCM 13507P) may result in a survival rate of 90% or more (preferably 95% or